Co-Authors
This is a "connection" page, showing publications co-authored by SUNIL KRISHNAN and GEORGE J CHANG.
Connection Strength
1.150
-
A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. J Gastrointest Oncol. 2022 Dec; 13(6):2938-2950.
Score: 0.227
-
MRI Staging in an Evolving Management Paradigm for Rectal Cancer, From the AJR Special Series on Cancer Staging. AJR Am J Roentgenol. 2021 12; 217(6):1282-1293.
Score: 0.204
-
Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):455-464.
Score: 0.154
-
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.
Score: 0.109
-
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer. 2020 06; 19(2):116-122.
Score: 0.047
-
Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
Score: 0.042
-
Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
Score: 0.040
-
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.
Score: 0.039
-
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.
Score: 0.038
-
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
Score: 0.038
-
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016 09 01; 34(25):3039-46.
Score: 0.037
-
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
Score: 0.030
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.030
-
Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013 Feb; 2(1):99-107.
Score: 0.029
-
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22.
Score: 0.025
-
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
Score: 0.022
-
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.
Score: 0.022
-
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
Score: 0.019